BridgeBio Pharma (NASDAQ:BBIO) Announces Earnings Results, Misses Estimates By $0.09 EPS

BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.96) EPS for the quarter, missing the consensus estimate of ($0.87) by ($0.09), Briefing.com reports. The business had revenue of $1.74 million during the quarter, compared to the consensus estimate of $4.78 million. BridgeBio Pharma’s revenue for the […]

Related Keywords

Frank Mccormick ,Hannah Valantine ,Bio Pharma ,Bridgebio Pharma ,Nasdaq ,Quantamental Technologies ,Bridgebio Pharma Inc ,Citigroup ,Cantor Fitzgerald ,Mercer Global Advisors Inc ,Wells Fargo Company ,Get Free Report ,Wells Fargo ,Director Hannah Valantine ,Director Frank Mccormick ,Street Markets ,Investment Management ,Mercer Global Advisors ,Bridgebio Pharma Daily ,Nasdaq Bbio ,Ebbio ,Medical ,Earnings ,